INTRoduCTIoN Methods MeTHodS oBjeCTIveS ...

LGF TPS6107 !,

,-26
(
)&+(%"72&
"'
(&"'.('
4"-!
!&(+"(-!+)6
@A
(+
%(%%6> Phase IB study of pembrolizumab in combination with chemoradiotherapy (CRT) LGFM
for 3'
,*2&(2,
%%
+"'(&
(
-!
!
'
'$
@ > A
locally-advanced squamous cell carcinoma of the head and neck (LA-SCCHN) !,

,-26
(
)&+(%"72&
"'
(&"'.('
4"-!
!&(+"(-!+)6
@A
(+
%(%%6>LGFM


2 1 2 1 1 3 G9
+$
2-2(-
"-2 H9
"%%"&
!+%,
)'(, G9
,!%6
6'
',' H9
6'
''-!
(4$ G9
"!%
(!+G9
2,'

22&%I9
!+",. Steven-3'
+'",
(4%% F. Powell1, Mark M. Gitau , William C. Spanos , Ashley W. Jensen , Ryan K. Nowak , Michele M. Lohr , Susan E. Puumala , LGFM
3'
,*2&(2,
%%
+"'(&
(
-!
!
'
'$
@ > A
!,

,-26
(
)&+(%"72&
"'
(&"'.('
4"-!
!&(+"(-!+)6
@A
(+
%(%%6> 3 3 4 5 5 5 1 Christie A. Ellison , Lora J. Black , Jonathan D. Cheng , Assuntina G. Sacco , Kathryn A. Gold , Ezra E.W. Cohen , John H. Lee I I J K K G

%%",(' 9
(+
'
%$ 9
('-!'
+
2+3"3%
@ •  -6
'
(%+"%"-6


))+(5"&-%6
LKF9FFF
" '(,,
)+
6+ Treatment

'-+(2.('
G Pembrolizumab 200 mg CRT? •  (&)%-
,)(',
@A
•  3+%%
2+3"3%
@A
 
  
 
  
Stage PRIMARY OBJECTIVES SECONDARY OBJECTIVES 1

))+(5"&-%6
LKF9FFF
" '(,,
)+
6+ Treatment days III-IVB Pembrolizumab 200 with approximately 
",
-!
L-!
&(,-
(&&('
&%" 650,000 diagnoses per year CRT? •  3+%%
2+3"3%
@A
• #.3,
(&)%-
,)(',
@A
Treatment Naïve Concurrent Treatment ''6
4(+%>4"
4"-!
+-
-
+-&'-
'
• 

((+ "('%
('-+(%
-
Adjuvant days •  
+&"',

,-'+
(
+9
2+.3
().('
(+
-7 (load), 15, 36 III-IVB Completed •  +( +,,"('>+
2+3"3%
@A

•  -6
'
(%+"%"-6
SCCHN? " 2+
H;
-26
!&
>
FHKNLHFM
Pembrolizumab 200 mg days 57, 78, 99, G Pembrolizumab 200 mg Stage • Safety and Tolerability • Progression-Free Survival (PFS)

'-+(2.('
))+(5"&-%6
LKF9FFF
" '(,,
)+
6+

@ A
• 

((+ "('%
('-+(%
-
+-
-
+-&'-
'
Treatment

> 
Weekly Cisplatin 40 mg/m2 •  
+&"',

,-'+
(
+9
2+.3
().('
(+
-7 (load), 15, 36  
  
 
  
•  3+%%
2+3"3%
@A
CRT? • 57, (&)%-
,)(',
@A
• CRT remains a standard of care, curative option for 120, 141 SCCHN? days mg days 78, 99, III-IVB •  ((+ ",-'-
-,-,",
@A
+-
Pembrolizumab 200 days 1, 8, 15,Treatment 22, 29, 36 •  K>6+
,2+3"3%
+-,
+&"'
%,,
-!'
KFR

• Complete Response (CR) • Overall Survival (OS) Yes Treatment Naïve Concurrent @ A
 
",
-!
L-!
&(,-
(&&('
&%" ''6
4(+%>4"
4"-!
Yes Adjuvant •  "('%
('-+(%
-
+-
-
+-&'-
'


> 
Weekly Cisplatin 40 mg/m2 •  
+&"',

,-'+
(
+9
2+.3
().('
(+
-7 (load), 15, 36 Completed mg days 57, 78,120, •  • +( +,,"('>+
2+3"3%
@A

•  -6
'
(%+"%"-6
SCCHN? LA-SCCHN ))+(5"&-%6
LKF9FFF
" '(,,
)+
6+G

99, ,-
(3+%%
+,)(',
+-
141 Radiation 70 Gy in 35 Pembrolizumab 200 mg Stage rate at Treatment End @ A
H
Treatment • Locoregional Control Rate (LCR)

> 
•  ",-'-
-,-,",
@A
+ &&2'
%+'
",
+".%
"'
-!
!(,-
+,)(',
-(
 Weekly Cisplatin 40 mg/m2 days 1, 8, 15, 22, 29, 36 •  K>6+
,2+3"3%
+-,
+&"'
%,,
-!'
KFR

•  3+%%
2+3"3%
@A
CRT? •  (&)%-
,)(',
@A
Yes fractions 120, 141 @A
Yes days III-IVB Pembrolizumab 200 •  ",-'-
-,-,",
@A
+-
1, 8, 15, 22, 29, 36 •  K>6+
,2+3"3%
+-,
+&"'
%,,
-!'
KFR

Yes -7days • Distant Metastasis (DM) rate • 5-year survival • rates remain less than 50% Yes 35 •  •  ((+ "('%
('-+(%
-
+-
-
+-&'-
'
•  ,-
(3+%%
+,)(',
+-

+&"',

,-'+
(
+9
2+.3
().('
(+
(load), 15, 36 Radiation 70 Gy in 
2,"'
-!

B
•  '-
-+',%.('%
+,+!
&(',-+-
-!-
-!
H
SCCHN?

&&2'
%+'
",
+".%
"'
-!
!(,-
+,)(',
-(
 H


> 


&&2'
%+'
",
+".%
"'
-!
!(,-
+,)(',
-(


mg days 57,Treatment 78, 99, Radiation 70 Gy in 35 PR, SD,120, or 141 Weekly Cisplatin 40 mg/m2 fractions fractions End days 1, 8, 15, 22, 29, 36 Salvage SurgeryYes PD Imaging Radiation 70 Gy in 35 Treatment PR, SD, or (if feasible) (PET/CT) fractions End

•  ,-
(3+%%
+,)(',
+-
@ A
• Best overall@A
response rate (ORR) ,2+36
)+( +&&
-!
+)-(+
G
@>GA
'
"-,
%" '
2 @A
Immune clearance is in the host response to CRT •  ",-'-
-,-,",
@A
+-
•  critical K>6+
,2+3"3%
+-,
+&"'
%,,
-!'
KFR

Yes @> G9
> HA
"'-+.('
&6
)%6

+(%
"'
• PRO using the FACT H&N survey •  
2,"'
-!

B
•  
2,"'
-!

B
•  '-
-+',%.('%
+,+!
&(',-+-
-!-
-!
•  '-
-+',%.('%
+,+!
&(',-+-
-!-
-!
•  ,-
(3+%%
+,)(',
+-

I9J
H
"&&2'
,)
(
 
2+"'
 Treatment ,2+36


&&2'
%+'
",
+".%
"'
-!
!(,-
+,)(',
-(
 )+( +&&
-!
+)-(+
G
@>GA
'
"-,
%" '
• Recent translational research demonstrated that the Safety and Survival PR, SD, or ,2+36
$"' '
$''!*$#
?
%%
6
(2-(&,
4"%%

)+( +&&
-!
+)-(+
G
@>GA
'
"-,
%" '
@A
End PD @> G9
> HA
"'-+.('
&6
)%6

+(%
"'
Follow-up &+(%"72&
",

!2&'"7


J
&('(%('%
'.(6
(++%-
4"-!
,%"'
> G
5)+,,"('
,
('
-!
$(
•  
2,"'
-!

B
Salvage Surgery programmed death receptor 1 (PD-1) and its ligand •  '-
-+',%.('%
+,+!
&(',-+-
-!-
-!
Imaging PD @> G9
> HA
"'-+.('
&6
)%6

+(%
"'

I9J
Biomarker Correlation – All efficacy outcomes will be Treatment Salvage Surgery "&&2'
,)
(
 
2+"'
 -!-
%($,
-!",
"'-+.('
'
&6
+,-(+
>%%
.3"-6
"'
> G

HHI
)!+&5
-,-
Imaging CR PR, SD, or (if feasible) ,2+36
Safety and Survival )+( +&&
-!
+)-(+
G
@>GA
'
"-,
%" '
(PET/CT) $"' '
$''!*$#
?
%%
6
(2-(&,
4"%%


I9J
"&&2'
,)
(
 
2+"'
 (PD-L1, PD-L2)&+(%"72&
",

!2&'"7


interaction may play a role in immune End -!",
,0'
(if feasible) PD correlated with baseline PD-L1 expression based on the Safety and Survival Follow-up J
&('(%('%
'.(6
@> G9
> HA
"'-+.('
&6
)%6

+(%
"'
(PET/CT) (++%-
4"-!
,%"'
> G
5)+,,"('
,
('
-!
$(
$"' '
$''!*$#
?
%%
6
(2-(&,
4"%%

Salvage Surgery 3,4 Imaging $''!*-
('

I9J
escape of SCCHN during CRT -!-
%($,
-!",
"'-+.('
'
&6
+,-(+
>%%
.3"-6
"'
•  >G
"'!"".('
"'
(&"'.('
4"-!
",)%.'>,
> G

HHI
)!+&5
-,-
"&&2'
,)
(
 
2+"'
 CR Follow-up &+(%"72&
",

!2&'"7
J
&('(%('%
'.(6
(++%-
4"-!
,%"'
> G
5)+,,"('
,
('
-!
$( Dako PD-L1 IHC 22C3 pharmDx test (if feasible) Safety and Survival (PET/CT) $"' '
$''!*$#
?
%%
6
(2-(&,
4"%%

-!",
,0'

,2 ,-,
,6'+ 6
"'

)+>%"'"%
 
&(2,
Follow-up " 2+
I;
6
'%2,"('
'
5%2,"('
+"-+"
J
&('(%('%
'.(6
-!-
%($,
-!",
"'-+.('
'
&6
+,-(+
>%%
.3"-6
"'
(++%-
4"-!
,%"'
> G
5)+,,"('
,
('
-!
$(
CR K Pembrolizumab is&+(%"72&
",

!2&'"7


a humanized IgG4 monoclonal antibody !$.
0)$")'0
> G

HHI
)!+&5
-,-
&(%
@" 2+
GA

$''!*-
('
•  >G
"'!"".('
"'
(&"'.('
4"-!
",)%.'>,
-!-
%($,
-!",
"'-+.('
'
&6
+,-(+
>%%
.3"-6
"'
> G

HHI
)!+&5
-,-
CR -!",
,0'
 
 

•  %"'"%
'%6,",
(
-!",
,-+- 6
",
4++'-
3*
5*
that blocks this interaction ,-,
,6'+ 6
"'

)+>%"'"%
 
&(2,
-!",
,0'
,2
" 2+
I;
6
'%2,"('
'
5%2,"('
+"-+"
"#*

*2&(2,
%%
+"'(&
(
-!
(+%
3"-6
+"(+
!&(-!+)69
+"(-!+)69
(+
K !$.
0)$")'0
&(%
@" 2+
GA

•  >G
"'!"".('
"'
(&"'.('
4"-!
",)%.'>,
$''!*-
('
@5%2"'
%")A9
(+()!+6'59
!6)()!+6'59
(+

"&&2'(-!+)6
(+
 
! !&% #
•  >G
"'!"".('
"'
(&"'.('
4"-!
",)%.'>,
• PD-1 inhibition in• combination with cisplatin-based  
 
%"'"%
'%6,",
(
-!",
,-+- 6
",
4++'-

3*
5*
!$$
%+6'5

,2 ,-,
,6'+ 6
"'

)+>%"'"%
 
&(2,

,2 ,-,
,6'+ 6
"'

)+>%"'"%
 
&(2,
" 2+
I;
6
'%2,"('
'
5%2,"('
+"-+"
" 2+
I;
6
'%2,"('
'
5%2,"('
+"-+"
"#*

*2&(2,
%%
+"'(&
(
-!
(+%
3"-6
+"(+
!&(-!+)69
+"(-!+)69
(+
CRT suggests synergy in a pre-clinical SCCHN mouse K Flow !$.
0)$")'0
!$.
0)$")'0
K - 


9
9
(+

- 

@",-'-
&-,-,,A
",,
" 2+
G
&(%
@"

"2+
GA 2+
G
&(%
@" 2+
GA

@5%2"'
%")A9
(+()!+6'59
!6)()!+6'59
(+

"&&2'(-!+)6
(+
 
! !&% #

 
 
Cytometry  
UGN
('2++'-
.3
&%" ''6
@5%2"'
,$"'
•  5 %"'"%
'%6,",
(
-!",
,-+- 6
",
4++'-

3*
5*
model (Figure 1) !$$
%+6'5
 
 
 
•  %"'"%
'%6,",
(
-!",
,-+- 6
",
4++'-
3*
5*
,%
%%
'
,*2&(2,
%%
+"'(&,A
"#*

*2&(2,
%%
+"'(&
(
-!
(+%
3"-6
+"(+
!&(-!+)69
+"(-!+)69
(+
CD4,& CD8,"
Tregs, - 


9
9
(+

- 

@",-'-
&-,-,,A
",,
&,##
" 2+
G
" 2+
G
"#*

*2&(2,
%%
+"'(&
(
-!
(+%
3"-6
+"(+
!&(-!+)69
+"(-!+)69
(+
@5%2"'
%")A9
(+()!+6'59
!6)()!+6'59
(+

"&&2'(-!+)6
(+
 
! !&% #


F>G
.3
"'.(',
• Clinical analysis of this strategy is warranted $"%
 
UGN
('2++'-
.3
&%" ''6
@5%2"'
,$"'
MDSC 
populations

&
 
!$$
%+6'5
@5%2"'
%")A9
(+()!+6'59
!6)()!+6'59
(+

"&&2'(-!+)6
(+
 


)! )$#
! !&% #
 
GG
'
2'.('
.3
"'.(',
$"%


&

)$#
 
UGN
('2++'-
.3
&%" ''6
@5%2"'
,$"'


)! ,"$'
- 


9
9
(+

- 

@",-'-
&-,-,,A
",,
 
 
GG

UGN
('2++'-
.3
&%" ''6
@5%2"'
,$"'
RNA $"%
IHC .3
"'.(',
 


&
,"$'
T
",)%.'
JF
& =&H
-.,.%
'%6,",


& "'
?

,%
%%
'
,*2&(2,
%%
+"'(&,A
Sequencing Tumor

)! )$#
 
G"( +)!"
(&)%-
+,)(',
@+A:(+









>(&)%-
-!
-+-&'-
'

"& "'
,-26

•  %())+>+,('
OKR
(''
"'-+3%
(+
-!
)+()(+. •  2%%
'%6,",
-
@A
)()2%.('
•  "' %>+&9
&2%.>,"-9
()'>%%
-+"%
(
)&+(%"72&
*$#

$()5*$#

,"$'
%"#(
the analysis of safety data ####$#
+'"'
#
!,'
6"7
-!(,










>
(&)%-
&-(%"
+,)(',
@A:(+








>"3
-
%,-
('
(,
(
,-26
-+-&'-9
@ >IJMKA
2,
"'
(&"'.('
4"-!
,-'+9
",)%.'>

(

(
%"'"%
"'-+,-
4"%%

,.&-
2,"'
5-
&,,,,&'-,
'
(%%(4>2)
• Clopper-Pearson 95% confidence interval for the proportion •  +-&'-9
-26
","-,9
'
(++%.3
,-26
)+(2+,
4!"%
('
.3
-+-&'-
"$,(
"$!4
A
+,)(',
+',

(((("#)










>-!(%( "
(&)%-
+,)(',
@)A
"
,%3 
,2+ +6









>(&)%-
-!
-+-&'-
'

"& "'
,-26

,9
'".3

"'
).'-,
4"-!
,- 


> 
 
•  "' %>+&9
&2%.>,"-9
()'>%%
-+"%
(
)&+(%"72&
####$#
+
(2-%"'
"'
" 2+
J
,
('
"'(&"%
",-+"2.('
6
52)
3%2-
(-!
-!
,-6
'
6
(
-!",
'(3%
G
(
GH
6BF7
+
(2-%"'
"'
" 2+
J
$''!*-
!$$

H>G
+(2)

A








>(&)%-
-!
-+-&'-
'

"& "'
,-26

'('
9
-
%%%
-+"%
(
)&+(%"72&
Efficacy (&"'.(' 
 
4"%%

'+(%%
-(
HFFO:GIK@GGA;GGIM>JLJL"3
-
%,-
('
(,
(
,-26
-+-&'-9
IGL-+-&'-
-2&(+
,)"&',
'
'6
,%3 
,2+ "%
,)"&',
4"%%

(%%-
HKIHFFGH
•  (++%.3
%((
,&)%,
(%%-
2+"'
-!+)6
'
-
GH
&('-!,
)(,->-+-&'-
•  6
'%2,"('
'
5%2,"('
+"-+"
+
%",-
"'
" 2+
I
Safety and Survival Follow-up







>(&)%-
-!
-+-&'-
'

"& "'
,-26

$'(4% &'-,
+$
!+)
B
(!&
(+)
'
'(+
,+!
-Receive at least one dose of study treatment, •  "' %>+&9
&2%.>,"-9
()'>%%
-+"%
(
)&+(%"72&
&('-!,
)(,->-+-&'-
####$#
(+
-+',%.('%
+,+!
J"$
9
-
% 
 
$'(4% &'-,
+
(2-%"'
"'
" 2+
J
progression at 3, 6, 12, 24, 36, 48, and 60 months (+
-+',%.('%
+,+!
G 
 
4"%%

'+(%%
-(
•  -26
2'
-!+(2 !
-!
+$
'3,. -(+
-2",
+( +&
@ A9
following treatment and neck imaging (CT) $)

&"''
  (,&!
with head •  (++%.3
%((
,&)%,
(%%-
2+"'
-!+)6
'
-
GH
&('-!,
)(,->-+-&'-
  )

  )GJ-+-&'-
-2&(+
,)"&',
'
'6
,%3 
,2+ "%
,)"&',
4"%%

(%%-
specimens will be collected for translational research $'(4% &'-,
(+
-+',%.('%
+,+!
Acknowledgements • Correlative blood samples collected during therapy and •  -26
2'
-!+(2 !
-!
+$
'3,. -(+
-2",
+( +&
@ •  (++%.3
%((
,&)%,
(%%-
2+"'
-!+)6
'
-
GH
&('-!,
)(,->-+-&'-


at 12 months post-treatment

+$
!+)
B
(!&
(+)
'
'(+
,+!
• Study funded through the Merck Investigator Studies Program (MISP), Merck Sharp & Dohme Corp and Sanford Research